[go: up one dir, main page]

ECSP11011420A - Procedimientos para mejorar la farmacocinética - Google Patents

Procedimientos para mejorar la farmacocinética

Info

Publication number
ECSP11011420A
ECSP11011420A EC2011011420A ECSP11011420A ECSP11011420A EC SP11011420 A ECSP11011420 A EC SP11011420A EC 2011011420 A EC2011011420 A EC 2011011420A EC SP11011420 A ECSP11011420 A EC SP11011420A EC SP11011420 A ECSP11011420 A EC SP11011420A
Authority
EC
Ecuador
Prior art keywords
pharmacocinetics
procedures
improve
cytochrome
raise
Prior art date
Application number
EC2011011420A
Other languages
English (en)
Inventor
Jonathan Q Tran
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP11011420A publication Critical patent/ECSP11011420A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

El objeto de la presente invención, es el de elevar los niveles en sangre de un compuesto de la fórmula I, mediante la co-administración con un inhibidor del citocromo P450.
EC2011011420A 2009-04-25 2011-10-25 Procedimientos para mejorar la farmacocinética ECSP11011420A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17272209P 2009-04-25 2009-04-25

Publications (1)

Publication Number Publication Date
ECSP11011420A true ECSP11011420A (es) 2011-11-30

Family

ID=42236685

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011420A ECSP11011420A (es) 2009-04-25 2011-10-25 Procedimientos para mejorar la farmacocinética

Country Status (36)

Country Link
US (4) US20100272682A1 (es)
EP (1) EP2421527B1 (es)
JP (1) JP5523552B2 (es)
KR (1) KR101471238B1 (es)
CN (2) CN105233249A (es)
AR (1) AR076388A1 (es)
AU (1) AU2010240893B2 (es)
BR (1) BRPI1015147B1 (es)
CA (1) CA2758644C (es)
CL (1) CL2011002643A1 (es)
CO (1) CO6440593A2 (es)
CR (1) CR20110551A (es)
DK (1) DK2421527T3 (es)
EC (1) ECSP11011420A (es)
ES (1) ES2683736T3 (es)
HK (1) HK1215858A1 (es)
HR (1) HRP20181306T1 (es)
HU (1) HUE040182T2 (es)
IL (1) IL215620A (es)
LT (1) LT2421527T (es)
MA (1) MA33212B1 (es)
MX (2) MX351185B (es)
MY (1) MY169734A (es)
NZ (1) NZ595917A (es)
PE (1) PE20120638A1 (es)
PL (1) PL2421527T3 (es)
PT (1) PT2421527T (es)
RS (1) RS57501B1 (es)
RU (1) RU2591830C2 (es)
SG (1) SG175328A1 (es)
SI (1) SI2421527T1 (es)
TR (1) TR201809600T4 (es)
TW (1) TWI468160B (es)
UA (1) UA103801C2 (es)
WO (1) WO2010122087A1 (es)
ZA (1) ZA201107421B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011004007A (es) * 2008-10-15 2011-05-19 Intermune Inc Peptidos antivirales terapeuticos.
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
ES2572328B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para su uso en el tratamiento del vhc
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US9346785B2 (en) 2012-01-11 2016-05-24 Abbvie Inc. Process for making HCV protease inhibitors
US20140024613A1 (en) * 2012-06-27 2014-01-23 Abbvie Inc. Methods for Treating HCV
CN104822682A (zh) 2012-10-08 2015-08-05 艾伯维公司 用于制备hcv蛋白酶抑制剂的化合物
DK3137078T3 (da) * 2014-05-01 2019-06-11 Eiger Biopharmaceuticals Inc Behandling af hepatitis delta-virusinfektion
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
ES2844848T3 (es) 2015-04-21 2021-07-22 Eiger Biopharmaceuticals Inc Composiciones farmacéuticas que comprenden Lonafarnib y Ritonavir
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
CN117105928B (zh) * 2023-08-22 2024-03-26 上海蓝木化工有限公司 一种蛋白酶抑制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2317977T3 (es) 1992-12-29 2009-05-01 Abbott Laboratories Procedimientos e intermediarios para la preparacion de inhibidores de proteasa retrovirales.
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
IL141438A0 (en) 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
MXPA03000626A (es) * 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
UA81003C2 (en) 2002-12-16 2007-11-26 Boehringer Ingelheim Int Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450
ATE416789T1 (de) * 2003-10-27 2008-12-15 Vertex Pharma Kombinationen für die hcv-behandlung
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
US20120220520A1 (en) * 2006-10-17 2012-08-30 Van T Klooster Gerben Albert Eleutherius Bioavailable combinations for hcv treatment

Also Published As

Publication number Publication date
JP5523552B2 (ja) 2014-06-18
IL215620A (en) 2015-10-29
TR201809600T4 (tr) 2018-07-23
RU2011142651A (ru) 2013-05-27
RU2591830C2 (ru) 2016-07-20
SG175328A1 (en) 2011-11-28
HUE040182T2 (hu) 2019-02-28
ES2683736T3 (es) 2018-09-27
US20170119739A1 (en) 2017-05-04
US10918626B2 (en) 2021-02-16
DK2421527T3 (en) 2018-08-13
TW201041582A (en) 2010-12-01
US20100272682A1 (en) 2010-10-28
MX2011011105A (es) 2011-11-18
ZA201107421B (en) 2022-11-30
BRPI1015147A2 (pt) 2018-01-30
AR076388A1 (es) 2011-06-08
PE20120638A1 (es) 2012-05-26
US20200230112A1 (en) 2020-07-23
KR101471238B1 (ko) 2014-12-12
CN102413827A (zh) 2012-04-11
UA103801C2 (ru) 2013-11-25
US20180318267A1 (en) 2018-11-08
HK1215858A1 (zh) 2016-09-23
AU2010240893A1 (en) 2011-11-03
EP2421527B1 (en) 2018-06-13
CA2758644A1 (en) 2010-10-28
CN105233249A (zh) 2016-01-13
CL2011002643A1 (es) 2012-05-25
BRPI1015147B1 (pt) 2022-03-08
JP2012524753A (ja) 2012-10-18
CO6440593A2 (es) 2012-05-15
RS57501B1 (sr) 2018-10-31
SI2421527T1 (sl) 2018-09-28
NZ595917A (en) 2014-02-28
PL2421527T3 (pl) 2018-10-31
CA2758644C (en) 2018-01-09
PT2421527T (pt) 2018-08-02
MX351185B (es) 2017-10-04
KR20120014170A (ko) 2012-02-16
IL215620A0 (en) 2012-01-31
MA33212B1 (fr) 2012-04-02
MY169734A (en) 2019-05-14
TWI468160B (zh) 2015-01-11
AU2010240893B2 (en) 2015-02-05
LT2421527T (lt) 2018-09-10
CR20110551A (es) 2011-12-13
EP2421527A1 (en) 2012-02-29
WO2010122087A1 (en) 2010-10-28
HRP20181306T1 (hr) 2018-10-19

Similar Documents

Publication Publication Date Title
ECSP11011420A (es) Procedimientos para mejorar la farmacocinética
ECSP12011573A (es) Compuestos tetracíclicos
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
ECSP13013074A (es) Nuevos derivados de piridina
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
EA201290800A1 (ru) Гетероциклическое соединение
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
GT201200230A (es) Inhibidores del virus de la hepatitis c
CR20130539A (es) Triazolopiridinas
CR20120295A (es) Triazolopiridinas
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
CR20130045A (es) Compuestos terapéuticos
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
UY34472A (es) Derivados modificados de 4-fenil-piridina
CR20150250A (es) Nuevos derivados de piridina
CR20110046A (es) Amidofenoxiindazoles utiles como inhibidores de c-met
UY32481A (es) Derivados de benzofurano
CR20120637A (es) Triazolopiridinas sustituidas
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas
UY34442A (es) 2-tiopirimidinonas.
CR20150084A (es) 2-oxo-2,3-dihidro-indoles
CO6761304A2 (es) Nuevos compuestos de bezodioxol-piperazina